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Abstract
Herpes simplex virus (HSV) is prevalent worldwide, with a recent report by the World Health Organization
estimating that 3.7 billion individuals under the age of 50 have been infected by the virus. After the initial
infection, HSV-1 enters a latent phase with the potential for intermittent reactivation, often secondary to
episodes of infection, stress, or immunosuppression. Per current literature review, esophageal
involvement in the form of herpes simplex virus esophagitis (HSVE) is more commonly associated with
immunocompromised patients, such as transplant recipients and HIV-positive individuals. The patient
discussed in this report is a 79-year-old female with a past medical history of COPD managed with a daily
prednisone dose of 10mg, as well as inhaled fluticasone-umeclidinium-vilanterol, inhaled ipratropiumalbuterol, and oral montelukast. During her acute COPD exacerbation, she was initially treated outpatient
with an increase in oral prednisone to 20mg daily. Once admitted, patient went on to receive an additional
ten days of intravenous methylprednisolone treatment for this prolonged COPD exacerbation. She
subsequently developed severe odynophagia refractory to nystatin oral suspension and fluconazole, as
thrush was initially expected. As symptoms worsened an EGD and biopsy were ordered, and the patient
was later diagnosed with Herpes simplex virus esophagitis. Ensuing HIV testing was negative. Patient
responded rapidly to IV Acyclovir, with resolution of symptoms within 48 hours. This unique case
highlights that HSVE can be a potential sequela of prolonged corticosteroid treatment for an acute COPD
exacerbation.
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CASE REPORT

An Unexpected Case of Herpes Simplex Virus
Esophagitis Presenting Amidst Corticosteroid
Therapy for an Acute COPD Exacerbation:
A Case Report*
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a
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Abstract
Herpes simplex virus (HSV) is prevalent worldwide, with a recent report by the World Health Organization estimating
that 3.7 billion individuals under the age of 50 have been infected by the virus. After the initial infection, HSV-1 enters a
latent phase with the potential for intermittent reactivation, often secondary to episodes of infection, stress, or immunosuppression. Per current literature review, esophageal involvement in the form of herpes simplex virus esophagitis
(HSVE) is more commonly associated with immunocompromised patients, such as transplant recipients and HIV-positive individuals. The patient discussed in this report is a 79-year-old female with a past medical history of COPD
managed with a daily prednisone dose of 10mg, as well as inhaled ﬂuticasone-umeclidinium-vilanterol, inhaled ipratropium-albuterol, and oral montelukast. During her acute COPD exacerbation, she was initially treated outpatient with
an increase in oral prednisone to 20mg daily. Once admitted, patient went on to receive an additional ten days of
intravenous methylprednisolone treatment for this prolonged COPD exacerbation. She subsequently developed severe
odynophagia refractory to nystatin oral suspension and ﬂuconazole, as thrush was initially expected. As symptoms
worsened an EGD and biopsy were ordered, and the patient was later diagnosed with Herpes simplex virus esophagitis.
Ensuing HIV testing was negative. Patient responded rapidly to IV Acyclovir, with resolution of symptoms within 48
hours. This unique case highlights that HSVE can be a potential sequela of prolonged corticosteroid treatment.
Keywords: Herpes, Herpes simplex virus, Herpes simplex virus esophagitis, COPD, Corticosteroids, Corticosteroid
therapy, COPD exacerbation, HSV-1, HSVE, Chronic obstructive pulmonary disease, Prednisone, Corticosteroid

1. Introduction

H

erpes simplex virus (HSV) has spread extensively throughout the global population, with
studies reporting that as much as 67% of the population has been infected by HSV-1.1,2 Whereas HSV-1
can be transmitted orally, HSV-2 is more frequently
sexually transmitted, explaining the gap in prevalence between the two types.2,3 Following a primary
oral infection, HSV-1 goes on to persist in a latent
phase with the potential for intermittent reactivation

due to immunodeﬁciency, stress, or illness.4 HSV
reactivation may even present with cutaneous or, less
commonly, ocular manifestations. However, in cases
of severe disease there may be evidence of neurological, respiratory, or even esophageal involvement.2,4 Herpes simplex virus esophagitis (HSVE) has
classically been more commonly associated with
immunocompromised patients, namely transplant
recipients and HIV-positive individuals.5
Incidences of herpes zoster reactivation, in general, have been evaluated among rheumatoid
arthritis patients on chronic corticosteroid therapy.

*
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Large population-based studies found that treatment with systemic corticosteroids of 10 mg or more
per day was associated with a statistically signiﬁcant
increase in the risk of herpes zoster reactivation.7
The following case discusses an instance of Herpes
simplex virus esophagitis arising amidst systemic
corticosteroid therapy for a prolonged exacerbation
of COPD.

2. Case presentation
A 79-year-old female with a past medical history
of chronic obstructive pulmonary disease (COPD)
on 3-L of oxygen at home, non-small cell lung cancer (NSCLC) s/p stereotactic body radiation therapy,
and a recent exacerbation of COPD treated with
corticosteroids presented to the emergency department with worsening shortness of breath over the
last week. Patient's COPD was being managed by
her primary care provider (PCP) with a regimen of
inhaled
ﬂuticasone-umeclidinium-vilanterol,
inhaled ipratropium-albuterol, oral montelukast,
and 10 mg of oral prednisone daily. Her at-home
medications included losartan, omeprazole, levothyroxine, amlodipine, aspirin, and atorvastatin.
Patient had seen her PCP four weeks earlier for
similar symptoms and was found to produce a
sputum culture positive for pan-sensitive Klebsiella
pneumoniae. She was diagnosed with a COPD
exacerbation and bronchiectasis and was then prescribed amoxicillin-clavulanate with an increased
dose of prednisone e now 20 mg total daily. However, her symptoms continued to worsen, necessitating an increase in her home oxygen requirements
from 2 to 3 L and, with further deterioration, hospital evaluation.
Review of systems was positive for a productive
cough, hemoptysis, shortness of breath, chills, and
malaise/fatigue. Physical examination in the emergency department revealed respiratory distress,
wheezing, prolonged expiration, and isolated systolic hypertension (182/68 mmHg). Pulse and respiratory rate were within normal limits, while SpO2
was at 94% on room air. Initial EKG and troponins
revealed no ischemia or arrhythmias. Further
testing revealed an elevated BNP (115 pg/mL),
leukocytosis (15.9 K/uL) with a neutrophilic predominance (85%), and lymphopenia (400/mm3).
Chest X-ray was ordered and signiﬁcant for
emphysema and left lower lobe alveolar disease and
nodularity, as seen in Fig. 1. Patient was admitted
for COPD exacerbation and suspected communityacquired pneumonia. Treatment with IV methylprednisolone 40 mg Q6H, IV ceftriaxone 1g, and PO
doxycycline 100 mg BID was initiated. During
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Fig. 1. Chest X-ray obtained upon patient presenting to Emergency
Department showed mild cardiomegaly and emphysema and suspected
scar tissue in the left lower lobe.

admission, shortness of breath continued to worsen,
and the patient began to experience gradual dyspnea on exertion. Transthoracic echocardiogram
was normal and a D-dimer test was also normal,
signiﬁcantly reducing the likelihood of pulmonary
embolism. PCR testing for SARS-CoV-2, Inﬂuenza
A, Inﬂuenza B, Adenovirus, Rhinovirus, and Parainﬂuenza virus were negative. Blood culture results
returned negative. Arterial Blood Gasses (ABGs)
drawn showed hypoxemia with a PO2 of 66 mmHg.
Patient's pH (7.41), PCO2 (39 mmHg), and HCO3 (25
mEq/l) were within normal limits.
On hospital day three, the patient began to show
signs of respiratory distress with increasing accessory muscle usage and was therefore transferred to
the intensive care unit. Here, Bilevel positive airway
pressure (BiPAP) was initiated. Follow-up ABGs
were within normal limits and the patient clinically
was beginning to show some signs of improvement.
However, although the patient was able to be
transferred out of the ICU, her overall clinical picture had not shown notable improvement after eight
days of Ceftriaxone and Doxycycline. A repeat
sputum culture grew Stenotrophomonas maltophilia
sensitive to Trimethoprim/Sulfamethoxazole (TMP/
SMX), so the patient was started on a seven-day
course. She reported some improvement in respiratory symptoms with TMP/SMX.
After ten days of intravenous methylprednisolone
treatment, the patient began to complain of a sore
throat/mouth and pain with swallowing. Patient was
initially treated for oral thrush with a nystatin oral
suspension, which did not lead to any symptom
improvement. Fluconazole was also initiated but the
odynophagia continued to worsen, and the patient

2

Khanani and Mirhadi: HSVE Presents Amidst Corticosteroid Therapy for COPD Exacerbation

was now struggling to eat and speak. On hospital
day ﬁfteen, gastroenterology was consulted and the
patient was referred for an esophagogastroduodenoscopy (EGD), during which hemorrhagic
esophagitis and several posterior pharyngeal erosions were noted and biopsied, as illustrated in
Fig. 2. Pathology report found H&E staining notable
for acute inﬂammatory exudate, neutrophils,
desquamated epithelial cells of the esophagus, and
viral inclusion bodies suggestive of a herpes simplex
virus infection, indicated by the arrow in Fig. 3.
Another ﬁeld view can be seen in Fig. 4, which
displays the acute inﬂammatory exudate with viral
inclusions that present as 3 nuclei with pale centers.
Finally, in Fig. 5, biopsies showed positive antibodyantigen immunohistochemical staining for herpes
simplex virus type 1.
Follow-up serology testing was positive for HSV-1
IgG. Notably, HIV antigen/antibody tests were
negative. Following these results, the patient was
started on IV Acyclovir. Patient reported signiﬁcant
improvement in symptoms after just two days of
treatment with the antiviral. Patient was kept an
additional day to monitor for tolerance with PO food
and medication intake. On hospital day twenty-one,
patient was discharged with an 11-day course of
Valtrex 1g to treat the Herpes Simplex Virus
Esophagitis for a total of fourteen days of antiviral
treatment and with a 30-day supply of Prednisone
20 mg.

Fig. 3. H&E stain showing acute inﬂammatory exudate (neutrophils)
and desquamated epithelial cells of the esophagus. Arrow is pointing to
cell with viral inclusion bodies suggestive of herpes infection.

3. Discussion
This report sought to highlight herpes simplex
virus esophagitis as a possible risk of prolonged
corticosteroid treatment. Though present literature
more commonly associates this manifestation of
HSV reactivation with transplant or HIV/AIDS patients, this case shows that herpes simplex virus
esophagitis should remain on the differential if that
patient is on corticosteroid therapy. Moreover, large

Fig. 4. The arrow points to acute inﬂammatory exudate on the right side
with cell containing viral inclusions (3 nuclei with pale center).

population-based observational studies reviewing
instances of HSV reactivation among rheumatoid
arthritis patients on chronic prednisone therapy
found statistically signiﬁcant increases in risk of
HSV reactivation in patients on at least 10 mg per

Fig. 2. Esophagogastroduodenoscopy showing posterior pharyngeal erosions and hemorrhagic esophagitis.
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HSV serology at various intervals of this disease
course would add to current literature in terms of
when to expect clinical improvements with this
antiviral treatment in patients made susceptible to
this disease due to prolonged corticosteroid use.

4. Conclusion

Fig. 5. Positive antibody-antigen immunohistochemical staining for
HSV-1.

day. Therefore, it is important to recall that the patient discussed in this case received ten days of IV
methylprednisolone 40 mg Q6H before ﬁnally
showing symptoms of odynophagia; and this was in
addition to the chronic 10 mg daily prednisone that
this patient had been taking for at least two years,
per chart review.
AAFP guidelines for management of COPD exacerbation note that high-dosage corticosteroid (over
30 mg daily) is beneﬁcial in terms of shortening
hospital stay and prolonging time between exacerbation among other beneﬁts.8 Clinicians should
therefore be aware of HSVE as a potential complication of corticosteroid therapy, especially given that
such an overwhelming majority of the population
has likely been exposed to HSV-1 and that COPD
itself is quite prevalent and the third leading cause of
death worldwide.1,6 Such risks of HSV reactivation
should be conveyed to patients when prescribing
corticosteroid courses greater than 10 mg daily. As a
result, patients with COPD, rheumatoid arthritis,
asthma, allergies, inﬂammatory bowel disease, and
other autoimmune conditions would be at risk given
their shared usage of corticosteroids for maintenance or abortive therapy.6
A limitation of the follow-up in this case is the
absence of a repeat EGD or HSV serology either
following the cessation of patient's symptoms or
after the full 14-day course of antiviral treatment.
This would allow the clinician to better evaluate
when completed remission occurred, whether it
occurred at all following 14 days, or if a longer
course was necessary despite resolution of symptoms. Literature does state that immunocompetent
hosts may response quickly when treated with
Acyclovir, though the recommended length of
treatment ranges from 14 to 21 days depending on
disease severity.5 Monitoring EGD ﬁndings and
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Herpes simplex virus esophagitis (HSVE) has
commonly been associated with immunosuppressed patients, speciﬁcally HIV-positive or
transplant patients. Nevertheless, prolonged corticosteroid treatments at doses of 10 mg or higher
have shown to increase the risk of HSV reactivation.
Physicians shoulder therefore keep in mind that
HSVE is a possible complication of long-term
corticosteroid therapy for an acute COPD
exacerbation.
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